Update on current best practices and the future of HFpEF (heart failure with preserved ejection fraction) with master cardiologist, Dr Clyde Yancy MD, Chief of Cardiology and Professor of Medicine (Cardiology) and Medical Social Sciences, Northwestern, Feinberg School of Medicine. Topics include: pathophysiology, HFpEF phenotypes, how to interpret a borderline ejection fraction, evidence based therapies, diuretics, and future directions (pulmonary artery monitors, interatrial shunts, ARNI compounds), and more!
Full show notes available at http://thecurbsiders.com/podcast. Join our mailing list and receive a PDF copy of our show notes every Monday. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com.
Written and produced by: Paul Williams MD, FACP; Sarah Phoebe Roberts MPH
Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP; Stuart Brigham MD
Show Notes: Justin Berk MD, MPH, MBA; and Beth Garbitelli MS1
Infographics: Beth Garbitelli MS1
Editor: Matthew Watto MD, FACP
Guest: Clyde Yancy MD, MSc, MACC, FAHA, MACP, FHFSA
The first discrimination point in CHF is preserved vs. reduced ejection fraction.
There are multiple phenotypes of HFpEF and they may have different therapeutic strategies.
The mortality rate of HFpEF is lower than HFrEF, but the morbidity may be worse.
There are no significant differences in physical exam findings between HFpEF and HFrEF.
For new HFpEF, there should be a coronary work-up. This may be initially done with coronary CT rather than catheterization.
New imaging strategies of the LAD may help predict which patients will have HFpEF.
New evidence suggests interatrial shunts may offer symptomatic and mortality benefit.
Basic treatment plan should include: diuresis for dyspnea, spironolactone (if elevated proBNP), SGLT2i if diabetes.
Future research is underway to evaluate SGLT2i in non-diabetics and sacubitril/valsartan (an ARNI compound) in HFpEF.
Heart Failure – The syndrome of shortness of breath, volume overload, and elevated natriuretic peptide.
Heart Failure with Preserved Ejection Fraction (HFpEF) – The first discrimination point in the heart failure syndrome. EF is considered ‘preserved’ if normal (i.e. >50%).
Ejection Fraction: How much blood is emitted with each contraction of the ventricle in comparison to how much blood is in the heart
Global Longitudinal Strain: Measures the deformation of the myocardium during systole. Less load dependent and more reflective of intrinsic ventricular functioning, contractility.
Diastolic Dysfunction – Specific hemodynamic consequences associated with valvular disease or ischemia.
Heart failure is the syndrome of shortness of breath, volume overload, and elevated natriuretic peptide often requiring hospital admission. The first discrimination point is the ejection fraction (EF). If the EF < 40%, this is Heart Failure with Reduced Ejection Fraction (HFrEF). If the EF is normal (i.e. >50%), this is HFpEF. In low EF with preserved strain, the ventricle may improve. Low EF and low strain is less favorable (Int J Cardiol Heart Vasc 2019). Up to 50% of patients with heart failure have preserved ejection fraction.
There is also a “gray zone” with a measured EF of 40 – 50%. Dr. Yancy suggests that this should be interpreted in context: e.g. a patient with known HFrEF and now has some improvement in ejection fraction may be different than a patient with HFpEF with worsening cardiac remodeling/ventricular weakening and lower ejection fraction.
HFpEF is an amalgam of different cardiac metabolic profiles and phenotypes that require unique approaches and need to be addressed with different prescribed therapies (i.e. Diabetes, AFib, HTN, Hyperlipidemia). For volume redistribution issues occurring in diabetic patients with obesity and a degree of renal insufficiency, physicians should take care not to over-diurese. SGLT2 inhibitors may be helpful for patients with diabetes/obesity/renal insufficiency. Patients with pulmonary hypertension may be more responsive to anti-ANP (ie: sacubitril) or antifibrotic therapy, like spironolactone. For patients with cardiorenal issues, it may be most important to optimize renal function.
Hypertension can lead to both HFrEF and HFpEF. Left ventricular hypertrophy (LVH) is not a required part of the pathophysiology. It may also be driven by a genetic predilection.
Research indicates that the pathophysiology of heart failure may be caused by a deficiency in nitric oxide and impairment in nitric oxide (NO) signaling. Obesity-driven upregulation of inflammatory markers may be one of the underlying etiologies in HFpEF. These inflammatory markers reduce cyclic GMP signaling activity, decreasing NO creation which leads to increasing reactive oxygen species, vascular compartment stiffness, damage, and fibrosis.
Outcomes for HFpEF are driven less by pump failure and cardiovascular death than by sudden cardiac death or acute coronary syndrome (JACC 2017; .
Many therapies for HFrEF have been successful in reducing hospitalizations, but this has not been the case for HFpEF: there are limited evidence-based therapies for reducing hospitalizations. Previous data is outdated: there has been improvement in outcomes, and mortality in HFpEF is lower than in HFrEF. Elevated natriuretic peptide levels are similary predictive of death in all CHF phenotypes.
Manage the underlying diabetes (if present) with comprehensive diet/lifestyle modification and adequate metformin therapy. Initiate discussion about SGLT2 inhibitors if indicated. Weight loss is associated with is associated with beneficial effects on cardiac structure and decreased hospitalization utilization.
Statin therapy is not indicated unless for other reasons (e.g. diabetes, CAD). This is true for beta-blocker treatment as well. ARB (ESC 2017) and spironolactone therapy have shown a small signal for improvement in HFpEF hospitalizations (see WikiJournal Club entry on TOPCAT).
New monitoring includes a wireless pulmonary arterial monitor that can help calibrate diuretic therapy, predict volume overload, and reduce future episodes of acute decompensated heart failure hospitalizations.
For HFpEF: Because ventricular volume is preserved, the pressure and volume differences in HFpEF are different. For any unit change in volume, there is a larger delta on pressure. This can significantly compromise renal blood flow if there is overdiuresis.
Dr Yancy points out that for patients with HFrEF, we often don’t augment diuresis nearly enough. Decompensation is not just symptoms, but causes a release of inflammatory cytokines and apoptotic signals. If not corrected quickly, the additional time spent exposed to adverse stimuli (cytokine environment) may make treatment more challenging.
Trials from the NHBLI Clinical Trial Network provided good evidence for initiating inpatient diuresis for congestion. Based on this work, Dr Yancy recommends doubling a patient’s home dose of furosemide and administering it IV two-three times daily. (Example:If the patient takes 60 mg QD of furosemide, they should start on 120mg IV furosemide 2-3 times a day for the first 48 – 72 hours).
Patients with new HFpEF need a workup for ischemic heart disease, as they have high likelihood of coronary artery disease (CAD). This could, but does not necessarily mean catheterization (which can increase renal insufficiency), as coronary CT may provide a simple, lower impact, binary answer to ‘Yes’ or ‘No’ on CAD.
For patients with exercise-induced symptoms of heart failure who are asymptomatic at rest, a right heart catheterization can identify the specific etiology.
Novel technology can now use transthoracic echocardiogram (TTE) to image left anterior descending artery and can then test for flow-mediated dysfunction and endothelial dysfunction (Eur Heart J Cardiovasc Imaging 2015). HFpEF is uniquely associated with endothelial flow mediated dysfunction. By non-invasively imaging the LAD to see flow pathologies, it may be possible to see if patient is at risk for complications of HFpEF.
Creating LA to RA shunts in patients with pHTN and HFpEF can help decompress left atrial hypertension. Elevated LA pressure causes the pulmonary hypertension and symptoms of heart failure. Preliminary data suggests a possible 33% reduction in mortality. Dr. Yancy notes that the study had limitations and further data is needed.
Diuretics relieve dyspnea, but do not alter the natural history of HFpEF. In HFpEF patients with elevated BNP, spironolactone might have a small reduction in HF hospitalizations (see foot note for 7.3.3 of 2017 ACC/AHA Focused Update).
Sacubitril / Valsartan (Entresto) was studied in PARAGON-HF, but did not show a decreased in the primary endpoint of heart failure hospitalizations or death from cardiovascular causes (PARAGON-HF, Solomon, 2019). Hopes were high since in animal labs, sacubitril regresses fibrosis and improves ventricular compliance. Similarly, angiotensin II receptor blockers (ARBs) have demonstrated improvement in hypertrophic cardiomyopathy. Thus, the thought was that these treatments would be targeting biology, not just the symptoms.
Listeners will differentiate HFpEF from HFrEF, explain its pathophysiology, and list the current possible future evidence based therapies for HFpEF.
After listening to this episode listeners will…
Dr Yancy reports no relevant financial disclosures. The Curbsiders report no relevant financial disclosures.
Axelsson A, Iversen K, Vejlstrup N, Ho C, Norsk J, Langhoff L, Ahtarovski K, Corell P, Havndrup O, Jensen M, et al. Lancet Diabetes Endocrinol. 2015 Feb; 3(2):123-31. Epub 2014 Dec 19.
https://www.ncbi.nlm.nih.gov/pubmed/25533774
Kaye DM, Petrie MC, McKenzie S, et al. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Fail. 2018;6(1):62–69. doi:10.1002/ehf2.12350
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351895/
Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013;10(4):401–410. doi:10.1007/s11897-013-0155-7
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870014/
Chan MMY, Lam CSP. How do patients with heart failure with preserved ejection fraction die? European Journal of Heart Failure. 2013;15(6):604-613. doi:10.1093/eurjhf/hft062.
https://www.ncbi.nlm.nih.gov/pubmed/23610137
Carolyn S P et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study, European Heart Journal, Volume 39, Issue 20, 21 May 2018, Pages 1770–1780.
https://www.ncbi.nlm.nih.gov/pubmed/29390051
Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res. 2014;115(1):79–96. doi:10.1161/CIRCRESAHA.115.302922
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4146618/
Feldman T et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I). Circ Heart Fail. 2016 Jul;9(7). pii: e003025. doi: 10.1161/CIRCHEARTFAILURE.116.003025.
https://www.ahajournals.org/doi/pdf/10.1161/CIRCHEARTFAILURE.116.003025
Shah SJ, Feldman T, Ricciardi MJ, et al. One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial. JAMA Cardiol. 2018;3(10):968–977. doi:10.1001/jamacardio.2018.2936
https://www.ncbi.nlm.nih.gov/pubmed/30167646
Felkner, GM et al. Diuretic strategies in patients with acute decompensated heart failure. NEJM. 2011; 364: 797-805.
Tromp J, Westenbrink BD, Ouwerkerk W, et al. Citation:Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. J Am Coll Cardiol 2018;72:1081-1090
DOI: 10.1016/j.jacc.2018.06.050
Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med 2016; 375:1868-1877
https://www.nejm.org/doi/full/10.1056/NEJMcp1511175
Lopez-Candales, Angel et al. Linking Chronic Inflammation with Cardiovascular Disease: From Normal Aging to the Metabolic Syndrome. Journal of nature and science vol. 3,4 (2017): e341.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488800/
Hayashi H, et al. S-Nitrosylation of β-Arrestins Biases Receptor Signaling and Confers Ligand Independence. J Molecular Cell 2018; 70. 3: 473-487.E6, MAY 03, 2018
DOI: https://doi.org/10.1016/j.molcel.2018.03.034
Yancy CW et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-e327.
https://www.ahajournals.org/doi/pdf/10.1161/CIR.0b013e31829e8776
Yancy CW et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–e161
https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000509
Pitt B et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370:1383-1392
https://www.nejm.org/doi/full/10.1056/NEJMoa1313731
Park J et al. Global Longitudinal Strain to Predict Mortality in Patients With Acute Heart Failure. Journal of the American College of Cardiology, May 2018, 71 (18) 1947-1957; DOI: 10.1016/j.jacc.2018.02.064
https://doi.org/10.1016/j.jacc.2018.02.064
Please feel free to reproduce, share and/or edit these wonderful show notes and figures! Just give us credit! Love, The Curbsiders Team
The Curbsiders are partnering with VCU Health Continuing Education to offer FREE continuing education credits for physicians and other healthcare professionals. Visit curbsiders.vcuhealth.org and search for this episode to claim credit.
Got feedback? Suggest a Curbsiders topic. Recommend a guest. Tell us what you think.
We love hearing from you.
Yes, you can now join our exclusive community of core faculty at Kashlak Memorial Hospital along with all the perks:
Notice
We and selected third parties use cookies or similar technologies for technical purposes and, with your consent, for other purposes as specified in the cookie policy. Denying consent may make related features unavailable.
Close this notice to consent.
Comments
I enjoy this podcast, this is a topic that I have been eager to learn more about but have limited exposure to in my primary care practice. Thanks